Themis starts Phase II trial of Chikungunya vaccine in the U.S.

8. June 2017

|In Portfolio News

|By eazee-designstudio

Sponsored by the National Institutes of Health, Themis Bioscience started a Phase II trial of its Chikungunya vaccine on a candidate in the U.S.